Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes: A Phase 1b Study
Doctors at the Loyola University Medical Center are recruiting patients with metastatic melanoma to trial a therapy of certain immune cells, or lymphocytes, that tend to infiltrate tumors (tumor-infiltrating lymphocytes, or TILs). These TILs will be extracted from the patient, gene-modified by a virus to better target the patient’s melanoma, and returned to the patient.
This investigatory treatment aims to assure the safety of various doses of the TILs. Patients will be monitored clinically and immunologically for a year after infusion.
- Be 18 to 89 years of age
- Have diagnosis of metastatic melanoma
- Meet criteria for any prior treatments or surgical operability
- Be HIV-negative
THE STUDY INVOLVES:
- Prescreening at the study site to confirm eligibility of the patient to participate.
- Apheresis, or collection of the patient’s white blood cells, will be conducted at the study site.
- No treatment while the cells are modified in the lab.
- One-time Infusion of the investigational drug made from the patient’s cells.
- Follow up at the study site location at a regular schedule for up to a year, assessing for adverse reactions.
LOCATIONS AND CONTACTS:
The study will take place at the Loyola University Medical Center in Maywood, IL. Map.
Michael Nishimura, PhD | 708-327-3241 | [email protected]
Ann Lau Clark, RN, MSN | 708-327-3221 | [email protected]
National Cancer Institute (NCI)
Or go online: